
Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
about 3 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)about 3 years ago
A New Era of Ethical Leadershipabout 3 years ago
Survival Story: Enhertuabout 3 years ago
Gut Instinct: Rebyotaabout 3 years ago
Delaying Disease Onset: Tzieldabout 3 years ago
New Beginnings: Sunlencaabout 3 years ago
A Heartfelt Solution: Camzyosabout 3 years ago
Fortifying Defenses Pre-Patent Cliffabout 3 years ago
New Product Planning: The Function's Evolution in Pharmaabout 3 years ago
No Rate Relief in Sight for BiotechAdvertisement
Related to this article

The future is agent-first but human when it matters — AI handles repetitive tasks while humans manage exceptions, complexity, and regulatory needs.

Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers whenever information is needed.

Pharma field forces face three key challenges: scaling services beyond tier one, shifting from reactive to proactive engagement, and empowering teams with agentic AI.
Advertisement
Advertisement
Trending on PharmExec
1
Keeping Human Expertise at the Center of AI
2
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
3
Build, Buy, or Rent: Moving AI Beyond the Pilot Stage
4
Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir
5

